These novel findings suggest that targeting mitochondrial Akt is a potential therapeutic approach to enhance cardiac insulin sensitivity in condition such as heart failure, diabetes and obesity. This evidence concerns the gene AKT1 and obesity due to melanocortin 4 receptor deficiency.